Pharmacokinetic study of a new formulation of elacridar

Completed

• Conditions: gezonde vrijwiliggers; na

• Registration Number: NL-OMON38922
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2014-12-01
• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 12

Inclusion Criteria

1. Healthy volunteer;
2. Age >=18 years;
3. Able and willing to give written informed consent;
4. Able and willing to undergo blood sampling for pharmacokinetic sampling;
5. Able and willing to swallow and retain oral medication;
6. Willing to comply to the protocol

Exclusion Criteria

1. Any treatment with investigational drugs within two weeks prior to receiving the first dose of investigational treatment;

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>pharmacokinetic properties of a new elacridar formulation</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>na</p><br>